Mengjie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mengjie Zhang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Yuanyu Huang
Beijing Institute of Technology
5 shared publications Haiyin Yang
2 shared publicationsKelong Fan
2 shared publicationsStefan Barth
2 shared publicationsXi Yu
School of Life Science, School of Interdisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering
2 shared publicationsZhuoran Wang
2 shared publications
Latest Publications
- 22 May 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (6) , 1318-1330
Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics
Hyperuricemia is a common metabolic disorder caused by purine metabolism dysregulation or impaired uric acid excretion, and it is closely associated with gout, chronic kidney disease, and cardiovascular diseases. Conventional treatments mainly rely on small-molecule drugs, such as xanthine oxidase inhibitors (e.g., allopurinol and febuxostat) and uricosuric agents (e.g., URAT1 inhibitors). However, these therapies still have limitations, including variable efficacy, poor long-term medication adherence, and potential adverse effects. With the advancement of RNA therapeutics, RNA-based strategies provide new directions for the precision management of hyperuricemia. Among them, small interfering RNA (siRNA) can suppress uric acid production or reduce renal tubular reabsorption by silencing genes encoding key metabolic enzymes or transporters (such as XOR/XDH or URAT1). In multiple animal models, this approach has demonstrated significant urate-lowering effects and renal protective benefits. Meanwhile, lipid nanoparticle (LNP)-delivered mRNA therapy restores the missing uric acid metabolic pathway in humans by re-expressing uricase in the liver. In animal models, this strategy can sustainably reduce serum uric acid levels and has shown favorable safety profiles. Therefore, the evolution from small-molecule inhibitors to RNA-based therapeutics not only expands the therapeutic targets for hyperuricemia but also promotes the development of personalized and precision medicine. In the future, with continuous improvements in delivery systems and RNA stability, RNA therapeutics are expected to become an important strategy for the long-term management of hyperuricemia.
- 22 May 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (6) , 1318-1330
Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics
Hyperuricemia is a common metabolic disorder caused by purine metabolism dysregulation or impaired uric acid excretion, and it is closely associated with gout, chronic kidney disease, and cardiovascular diseases. Conventional treatments mainly rely on small-molecule drugs, such as xanthine oxidase inhibitors (e.g., allopurinol and febuxostat) and uricosuric agents (e.g., URAT1 inhibitors). However, these therapies still have limitations, including variable efficacy, poor long-term medication adherence, and potential adverse effects. With the advancement of RNA therapeutics, RNA-based strategies provide new directions for the precision management of hyperuricemia. Among them, small interfering RNA (siRNA) can suppress uric acid production or reduce renal tubular reabsorption by silencing genes encoding key metabolic enzymes or transporters (such as XOR/XDH or URAT1). In multiple animal models, this approach has demonstrated significant urate-lowering effects and renal protective benefits. Meanwhile, lipid nanoparticle (LNP)-delivered mRNA therapy restores the missing uric acid metabolic pathway in humans by re-expressing uricase in the liver. In animal models, this strategy can sustainably reduce serum uric acid levels and has shown favorable safety profiles. Therefore, the evolution from small-molecule inhibitors to RNA-based therapeutics not only expands the therapeutic targets for hyperuricemia but also promotes the development of personalized and precision medicine. In the future, with continuous improvements in delivery systems and RNA stability, RNA therapeutics are expected to become an important strategy for the long-term management of hyperuricemia.
- Open Access
- 13 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 6082-6086
Unlocking the potential of targeted protein degradation via nanoparticle-based universal strategy
- 13 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 6082-6086
Open AccessUnlocking the potential of targeted protein degradation via nanoparticle-based universal strategy
- Open Access
- 1 September 2025
- Published by KEAI Publishing in Fundamental Research
- Vol. 5 (5) , 1920-1929
Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy
Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1. In vitro and in vivo studies demonstrate that the developed nanoparticle exhibits high levels of silencing efficiency, antitumor activity, and therapeutic efficacy. Consequently, this study provides a novel approach to cancer treatment by simultaneously disrupting two stages of tumor cell division.
- 1 September 2025
- Published by KEAI Publishing in Fundamental Research
- Vol. 5 (5) , 1920-1929
Open AccessTumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy
Small interfering RNA (siRNA) has shown promising therapeutic prospects in many major diseases. However, two main reasons limit the application of siRNA: poor endocytosis efficiency and weak endosomal escape ability. Therefore, the development of efficient and safe delivery vectors has always been an important study aspect of RNAi technology. Herein, we designed a self-assembled nanoparticle based on functionalized peptides to deliver siRNA to the down-regulated polo-like kinase 1 (PLK1) gene, which can inhibit tumor cells in the G2 phase. The functional polypeptide consists of cell membrane-penetrating peptide (CPP44) and p16 minimal inhibitory sequence (p16MIS). CPP44 can effectively mediate endocytosis, while p16MIS can inhibit tumor growth in the G1 phase and synergistically promote the apoptosis of tumor cells with siPLK1. In vitro and in vivo studies demonstrate that the developed nanoparticle exhibits high levels of silencing efficiency, antitumor activity, and therapeutic efficacy. Consequently, this study provides a novel approach to cancer treatment by simultaneously disrupting two stages of tumor cell division.
- Top Cited PapersOpen Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Cyborg and Bionic Systems
- Vol. 6
Carrier-Free Peptide–Daunorubicin–Small Interfering RNA Nanoassembly for Targeted Therapy of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) continues to represent a substantial unmet therapeutic need in clinical practice. In recent years, peptide–drug conjugates and small interfering RNA (siRNA) drugs have gained considerable attention due to their impressive clinical progress in treating various diseases. In this study, we designed a carrier-free “3-in-1” peptide–daunorubicin–siRNA (PDR) nanoassembly, which combines a cell-penetrating and tumor-suppressing peptide, a daunorubicin (DNR) prodrug, and siRNA targeting the LILRB4 gene. After optimizing the molar ratio among peptide, DNR prodrug, and siRNA, we identified the most potent PDR formulation, which exhibited excellent intracellular uptake efficiency, primarily through caveolin-mediated endocytosis, in THP-1 cells. The pH-responsive bond in the DNR prodrug facilitated the endosomal escape of siRNA, leading to significant gene repression of LILRB4. Additionally, the tumor-suppressing peptide p16 MIS effectively inhibited the transition of cells from the S phase to the G2/M phase and induced apoptosis. In a leukemia mouse model, PDR efficiently suppressed leukemia cell invasion, prolonged survival, and reduced leukemia cell infiltration in the bone marrow. Notably, silencing LILRB4 not only promoted T cell maturation in spleen and lymph nodes but also enhanced T cell infiltration in tumor tissues. This study offered a highly promising therapeutic strategy for AML and other diseases.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Cyborg and Bionic Systems
- Vol. 6
Top Cited PapersOpen AccessCarrier-Free Peptide–Daunorubicin–Small Interfering RNA Nanoassembly for Targeted Therapy of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) continues to represent a substantial unmet therapeutic need in clinical practice. In recent years, peptide–drug conjugates and small interfering RNA (siRNA) drugs have gained considerable attention due to their impressive clinical progress in treating various diseases. In this study, we designed a carrier-free “3-in-1” peptide–daunorubicin–siRNA (PDR) nanoassembly, which combines a cell-penetrating and tumor-suppressing peptide, a daunorubicin (DNR) prodrug, and siRNA targeting the LILRB4 gene. After optimizing the molar ratio among peptide, DNR prodrug, and siRNA, we identified the most potent PDR formulation, which exhibited excellent intracellular uptake efficiency, primarily through caveolin-mediated endocytosis, in THP-1 cells. The pH-responsive bond in the DNR prodrug facilitated the endosomal escape of siRNA, leading to significant gene repression of LILRB4. Additionally, the tumor-suppressing peptide p16 MIS effectively inhibited the transition of cells from the S phase to the G2/M phase and induced apoptosis. In a leukemia mouse model, PDR efficiently suppressed leukemia cell invasion, prolonged survival, and reduced leukemia cell infiltration in the bone marrow. Notably, silencing LILRB4 not only promoted T cell maturation in spleen and lymph nodes but also enhanced T cell infiltration in tumor tissues. This study offered a highly promising therapeutic strategy for AML and other diseases.
- Open Access
- 1 February 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 32, 124-146
Exosome regulation of immune response mechanism: Pros and cons in immunotherapy
Due to its multiple features, including the ability to orchestrate remote communication between different tissues, the exosomes are the extracellular vesicles arousing the highest interest in the scientific community. Their size, established as an average of 30–150 nm, allows them to be easily uptaken by most cells. According to the type of cells-derived exosomes, they may carry specific biomolecular cargoes used to reprogram the cells they are interacting with. In certain circumstances, exosomes stimulate the immune response by facilitating or amplifying the release of foreign antigens-killing cells, inflammatory factors, or antibodies (immune activation). Meanwhile, in other cases, they are efficiently used by malignant elements such as cancer cells to mislead the immune recognition mechanism, carrying and transferring their cancerous cargoes to distant healthy cells, thus contributing to antigenic invasion (immune suppression). Exosome dichotomic patterns upon immune system regulation present broad advantages in immunotherapy. Its perfect comprehension, from its early biogenesis to its specific interaction with recipient cells, will promote a significant enhancement of immunotherapy employing molecular biology, nanomedicine, and nanotechnology.
- 1 February 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 32, 124-146
Open AccessExosome regulation of immune response mechanism: Pros and cons in immunotherapy
Due to its multiple features, including the ability to orchestrate remote communication between different tissues, the exosomes are the extracellular vesicles arousing the highest interest in the scientific community. Their size, established as an average of 30–150 nm, allows them to be easily uptaken by most cells. According to the type of cells-derived exosomes, they may carry specific biomolecular cargoes used to reprogram the cells they are interacting with. In certain circumstances, exosomes stimulate the immune response by facilitating or amplifying the release of foreign antigens-killing cells, inflammatory factors, or antibodies (immune activation). Meanwhile, in other cases, they are efficiently used by malignant elements such as cancer cells to mislead the immune recognition mechanism, carrying and transferring their cancerous cargoes to distant healthy cells, thus contributing to antigenic invasion (immune suppression). Exosome dichotomic patterns upon immune system regulation present broad advantages in immunotherapy. Its perfect comprehension, from its early biogenesis to its specific interaction with recipient cells, will promote a significant enhancement of immunotherapy employing molecular biology, nanomedicine, and nanotechnology.